| Imagery Source: Axios
Information Source: Johnson & Johnson |
- 2025 First-Quarter reported sales growth of 2.4% to $21.9 billion with operational growth of 4.2%* and adjusted operational growth of 3.3%*
|
- 2025 First-Quarter earnings per share (EPS) increased to $4.54, which includes the reversal of special charges, and adjusted EPS increased to $2.77 or 2.2%*
|
- Significant new product pipeline progress, including approval of TREMFYA in Crohn’s disease, data for RYBREVANT/LAZCLUZE overall survival in non-small cell lung cancer and ictotrokinra in plaque psoriasis, and initiation of the clinical trial for a general surgery robotic system, OTTAVA
|
- Company increases Full-Year 2025 operational sales2,5 guidance to reflect the addition of CAPLYTA following the completion of the Intra-Cellular Therapies acquisition
|
- Including tariff costs, dilution from the Intra-Cellular Therapies acquisition, and updated foreign exchange, the Company maintains a Full-Year 2025 adjusted reported EPS4 outlook of 6.2%* growth at the mid-point
|
| Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2025. “The power of Johnson & Johnson’s uniquely diversified portfolio was on full display this quarter, with strong operational sales growth reinforcing our confidence in 2025 guidance,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “During the quarter, we fortified our position as an innovation powerhouse with major advancements across our pipeline, including TREMFYA in IBD, RYBREVANT plus LAZCLUZE in non-small-cell lung cancer, and OTTAVA, our soft tissue surgical robotic system, and further enhanced our leading neuroscience portfolio with the completion of the Intra-Cellular Therapies acquisition.” |
| First-Quarter 2025 segment commentary: |
| Operational sales* reflected below excludes the impact of translational currency. |
| Innovative Medicine |
| Innovative Medicine worldwide operational sales grew 4.2%*, driven primarily by DARZALEX, CARVYKTI, ERLEADA, and RYBREVANT/LAZCLUZE in Oncology, TREMFYA and SIMPONI/SIMPONI ARIA in Immunology, SPRAVATO in Neuroscience, and XARELTO in Cardiovascular/Metabolism/Other. Growth was partially offset by an approximate (810) basis points impact from STELARA in Immunology. |
| MedTech |
| MedTech worldwide operational sales grew 4.1%*, with net acquisitions and divestitures positively impacting growth by 2.8%. Growth was driven primarily by Abiomed in Cardiovascular and wound closure products in General Surgery. Growth was partially offset by Spine, Sports & Other in Orthopaedics. |
| Full-year 2025 guidance: |
| Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the outcome of legal proceedings, unusual gains and losses, acquisition-related expenses, and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed by GAAP. |
| For the full document, click the link below |
| Johnson & Johnson |
| Stay ahead of the curve! Subscribe to InsidEntity for daily updates on all your favourite companies. |
